No exact match found for antibody‐mediated, using antibody mediated instead...
Results overview: Found 2 records in 0.03 seconds.
Articles, 2 records found
Articles 2 records found  
1.
9 p, 709.4 KB Rituximab, plasma exchange and immunoglobulins : an ineffective treatment for chronic active antibody-mediated rejection / Piñeiro, Gastón J. (Hospital Clínic i Provincial de Barcelona) ; De Sousa-Amorim, Erika (Hospital Clínic i Provincial de Barcelona) ; Solé, Manel (Hospital Clínic i Provincial de Barcelona) ; Ríos, José (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Lozano, Miguel (Hospital Clínic i Provincial de Barcelona) ; Cofan, Frederic (Hospital Clínic i Provincial de Barcelona) ; Ventura-Aguiar, Pedro (Hospital Clínic i Provincial de Barcelona) ; Cucchiari, David (Hospital Clínic i Provincial de Barcelona) ; Revuelta, Ignacio (Hospital Clínic i Provincial de Barcelona) ; Cid, Joan (Hospital Clínic i Provincial de Barcelona) ; Palou, Eduard (Hospital Clínic i Provincial de Barcelona) ; Campistol Plana, Josep M (Hospital Clínic i Provincial de Barcelona) ; Oppenheimer, Federico (Hospital Clínic i Provincial de Barcelona) ; Rovira, Jordi (Red de Investigación Renal (REDinREN)) ; Diekmann, Fritz (Hospital Clínic i Provincial de Barcelona)
Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a cohort of patients with transplant glomerulopathy (TG) that met criteria of active cABMR, according to BANFF'17 classification, was identified. [...]
2018 - 10.1186/s12882-018-1057-4
BMC Nephrology, Vol. 19 (october 2018)  
2.
14 p, 167.5 KB The Banff 2015 Kidney Meeting Report : Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology / Loupy, Alexandre (Paris Translational Research Center for Organ Transplantation INSERM U970 & Necker Hospital University Paris Descartes) ; Haas, Mark (Cedars-Sinai Medical Center) ; Solez, Kim (University of Alberta) ; Racusen, L. (Johns Hopkins University School of Medicine) ; Glotz, Denis (Université Paris VII and INSERM U 1160. Hopital Saint Louis) ; Serón Micas, Daniel (Hospital Universitari Vall d'Hebron) ; Nankivell, B. J. (Westmead Hospital) ; Colvin, Robert (Harvard Medical School) ; Afrouzian, Marjan (University of Texas Medical Branch) ; Akalin, Enver (Albert Einstein College of Medicine) ; Alachkar, Nada (Johns Hopkins University School of Medicine) ; Bagnasco, Serena (Johns Hopkins University School of Medicine) ; Becker, Jan U (Uniklinik Köln (Colònia, Alemanya)) ; Cornell, Lynn (Mayo Clinic) ; Drachenberg, C. (University of Maryland School of Medicine) ; Dragun, Duska (Charité - Universitätsmedizin Berlin) ; de Kort, H. (Leiden University Medical Center) ; Gibson, I. W. (University of Manitoba) ; Kraus, E. S. (Johns Hopkins University School of Medicine) ; Lefaucheur, Carmen (Université Paris VII and INSERM U 1160. Hopital Saint Louis) ; Legendre, C. (Paris Translational Research Center for Organ Transplantation INSERM U970 & Necker Hospital University Paris Descartes) ; Liapis, H. (Washington University) ; Muthukumar, T. (New York Presbyterian Hospital-Weill Cornell Medicine) ; Nickeleit, V. (University of North Carolina) ; Orandi, B. (Johns Hopkins University School of Medicine) ; Park, W. (Mayo Clinic) ; Rabant, Marion (Université de Paris) ; Randhawa, P. (University of Pittsburgh. The Thomas E Starzl Transplantation Institute) ; Reed, E. F. (University of California) ; Roufosse, C. (Hammersmith Hospital (Londres)) ; Seshan, S. V. (Weill Cornell Medicine) ; Sis, B. (University of Alberta) ; Singh, H. K. (University of North Carolina) ; Schinstock, C. (Mayo Clinic) ; Tambur, Anat R. (Northwestern University. Transplant Immunology Laboratory) ; Zeevi, Adriana (University of Pittsburgh Medical Center) ; Mengel, Michael (University of Alberta) ; Universitat Autònoma de Barcelona
The Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection () from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti- and non-) with transplant histopathology, and questions of molecular transplant diagnostics. [...]
2017 - 10.1111/ajt.14107
American Journal of Transplantation, Vol. 17, Issue 1 (January 2017) , p. 28-41  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.